96 results about "HPV infection" patented technology

The present application relates to a polynucleotide molecule that can be used for preventing or treatment HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

The invention provides a biomarker for cervical lesion caused by low folic acid mediated HPV infection and application of the biomarker, the biomarker is IGF2BP3 and miR-27a, and the IGF2BP3 and the miR-27a can be used as a therapeutic target and a research tool for cervical lesion caused by low folic acid mediated HPV infection. The small nucleic acid targeting IGF2BP3 and miR-27a is delivered through the folic acid modified exosome in cervical lesion treatment, and the delivery efficiency and the treatment effect are remarkably improved.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

The present application relates to a kind of traditional Chinese medicine for treating female HPV infection, which is prepared from the following weight ratio of traditional Chinese medicine raw materials: 2-4 parts of catechu, 2-4 parts of half lotus, 2-4 parts of snakeberry, 1-2 parts of longjin, 1-2 parts of gotu kola, 1-2 parts of wintergreen, 1-2 parts of coptis, and 1-2 parts of sophora. The present application can effectively treat female HPV infection.

The invention belongs to the field of biological medicine, and relates to a traditional Chinese medicine composition for treating high-risk HPV infection. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: radix sophorae flavescentis, rhizoma smilacis glabrae, fructus cnidii, cyrtomium fortunei, dried alum, pericarpium zanthoxyli, cortex phellodendri and raw radix stemonae.

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and / or HRAS along with detecting or determining an HPV infection.

The invention discloses application of berberine or berberine hydrochloride in preparation of drugs for resisting HPV infection related diseases. Preferably, the berberine is an extract of natural plants such as coptis chinensis, golden cypress, berberis poiretii schneid or Chinese mahonia. According to the application, the new application of the berberine or the hydrochloride thereof in the aspect of resisting the HPV virus is expanded, and the berberine or the hydrochloride thereof is used for preparing the preparation for resisting the HPV infection, so that diseases related to the HPV infection can be prevented or treated, and the virus is promoted to become negative. As a natural plant extract, berberine is high in safety and not easy to generate drug resistance, and has important clinical significance when being used for preparing Chinese patent medicine products for resisting HPV infection.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The invention relates to the field of biological medicine, in particular to a medicine for treating HPV infection related diseases. The invention provides antigen combinations, fusion proteins and encoding nucleic acids. The materials are used for preparing self-replicating RNA vaccines for treating cervical HPV persistent infection, intraepithelial neoplasia induced by the cervical HPV persistent infection and cervical cancer, and indications can be expanded to HPV long-term infected people. Therefore, not only can virus host cells be removed to treat long-term infection, but also precancerous lesions and cervical cancer can be treated more effectively.

The present application relates to the technical field of HPV repair, in particular to a long-acting sustained-release device combination for treating female vaginal HPV infection and a use method thereof, which provides a safe, low-irritation and convenient-to-use drug delivery mode, and comprises a vaginal drug delivery device A and a device B used in cooperation with each other, the magnetic therapy of the vaginal drug delivery device A can promote capillary dilation and improve microcirculation, the IgY in the drug sustained-release layer of the vaginal drug delivery device A can be stably kept in the gel at a high titer, the alginate sulfate-carboxymethyl chitosan composite microemulsion makes the drug more easily gathered at the infection site, the magnetic therapy and the sustained-release drug interact with each other, promote the absorption and dissipation of inflammation, and produce a good repair environment, the functional powder dressing of the subsequent vaginal drug delivery device B is convenient for mild absorption of the exudate on the surface of the vagina after the magnetic therapy and the drug sustained-release treatment without causing discomfort, and the functional powder dressing releases various ions at a certain rate, further repairing damaged cells and tissues.

The present invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for anti-HPV virus and its related applications. As a medicine for the treatment and prevention of HPV infection, the traditional Chinese medicine composition takes clearing heat and detoxifying, expelling toxins outwards, removing stasis and promoting new growth as the main treatment principles, and comprises the following raw materials: indigo naturalis, coptis chinensis, polygonum cuspidatum, talc, astragalus membranaceus, liquorice, saxicola undulata, gleditsia sinensis thorn, bletilla striata, chaenomeles sinensis, dragon's blood and borneol. The composition of the present invention has been clinically used for more than 5 years and is found to have a good effect on clearing high-risk HPV infection in the cervix and vagina. The clearance rate can reach more than 80% after 3 to 6 months of clinical local medication, indicating that the traditional Chinese medicine composition has an anti-HPV virus effect. After being wrapped by nanomaterials, the traditional Chinese medicine composition can effectively protect the active molecule while slowly and continuously exerting its efficacy, effectively clearing the cervix and playing an anti-HPV virus role.

The invention discloses a nano vaccine for treating HPV (human papilloma virus) infection related cervical lesions as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. In order to solve the problem that the response rate of an existing cervical lesion treatment vaccine does not meet clinical requirements, the hybrid membrane with enhanced immunogenicity and improved safety is prepared by applying a membrane fusion technology and combining an autologous tumor cell membrane and an escherichia coli cytoplasmic membrane; meanwhile, PLGA nano particles loaded with HPV16 E5 / E6 / E7 specific CTL epitope long peptide are used as a delivery carrier, and the HM-NPs-LP nano vaccine co-delivering the hybrid membrane and the HPV16 specific antigen peptide is developed. According to the nano vaccine, tumor cells and HPV16 E5 / E6 / E7 specific CTL epitope long peptide are taken as antigens for immunotherapy, dual immune activation of broad spectrum and specific antigens can be realized, personalized multi-effect treatment capacity for HPV infection related cervical diseases is exerted, targeted killing of HPV infection and pathological cells is enhanced, pathological relapse is prevented, and the nano vaccine has good clinical application prospects. And a new strategy is provided for individualized precise immunotherapy.

The invention relates to the technical field of traditional Chinese medicine preparation, in particular to a traditional Chinese medicine composition for inhibiting HPV infection and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials: rhizoma smilacis glabrae, radix sophorae flavescentis, herba houttuyniae, honeycomb, dysosma versipellis, fructus cnidii and brucea javanica. The preparation method comprises the following steps: (1) crushing brucea javanica, and preparing brucea javanica oil through supercritical extraction; (2) mixing fructus cnidii and dysosma versipellis to obtain a mixture A, adding ethanol for extraction, and performing solid-liquid separation to obtain an alcohol extract; (3) mixing radix sophorae flavescentis, herba houttuyniae, rhizoma smilacis glabrae and nidus vespae to obtain a mixture B, adding water for extraction, and performing solid-liquid separation to obtain a water extract; and (4) uniformly mixing the brucea javanica oil, the alcohol extract and the water extract. Liquid carbon dioxide and a deep-eutectic solvent are adopted in the supercritical extraction, and the deep-eutectic solvent is composed of quaternary ammonium salt and organic acid. The traditional Chinese medicine composition prepared by the invention is better in HPV infection inhibition effect and lower in side effect.

The present disclosure provides compounds having a structure set forth in formula (I), (I-1), (I-2), (I-3), (I-4), (II), (III) or (IV) the stereoisomer or a pharmaceutically acceptable salt, prodrug, or solvate thereof. Further provided are uses of the formula (I), (I-1), (I-2), (I-3), (I-4), (II), (III) or (IV), the stereoisomer or a pharmaceutically acceptable salt, prodrug, or solvate salt thereof in the prophylaxis or treatment of viral infection, especially HPV infection.

The application discloses a gel preparation preparation method for improving cervical HPV infection and establishing a preventive barrier, relates to the technical field of gel preparation, and aims to solve the technical problems that the existing treatment methods are mostly focused on treating infected patients, and there are obvious deficiencies in the prevention of HPV infection, especially in establishing an effective preventive barrier in uninfected people, including: a crushing mechanism, which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel is arranged on the cabinet door; a reverse osmosis mechanism, which is mainly used for controlling the osmotic pressure of the gel. The application has the advantages of activating local immune cells of the cervix, promoting cytokine secretion, enhancing the immune clearance ability of the body to HPV virus, providing long-acting preventive protection for the cervix, and reducing the risk of HPV infection.

A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to lactobacillus delbrueckii with a killing effect on HPV (human papillomavirus) infected cervical epithelial cells or cervical cancer cells and application of the lactobacillus delbrueckii. The classification name of the lactobacillus delbrueckii is Lactobacillus delbrueckii, the preservation number is CGMCC No.32049, the preservation time is September 24, 2024, the preservation place is China General Microbiological Culture Collection Center (CGMCC), and the address of the preservation unit is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing. The lactobacillus delbrueckii disclosed by the invention is expected to become a treatment scheme for treating HPV infection, cervical intraepithelial neoplasia and even cervical cancer, and has a relatively high clinical application value and a wide market prospect.

The invention discloses a medicine slow-release device for cervical HPV infection, which comprises a cylinder, the top of the cylinder is hermetically connected with an end, the end is provided with medicine outlets at equal angles, and the middle of the bottom surface of the cylinder is connected with a piston rod in a penetrating manner; a protective cover is hinged to the top of the barrel at equal angles, the protective cover covers the outer side of the end, a regulation and control mechanism is arranged on the inner side of the bottom of the barrel, the regulation and control mechanism drives the protective cover to rotate in an opening and closing mode in a meshing rotation mode, and meanwhile the protective cover is used for protecting the end; an installation locking mechanism is arranged on the cylinder body, and the installation locking mechanism is used for firmly connecting the end heads in a rotating connection mode. According to the medicine slow release device for cervical HPV infection, the cleanliness of the medicine delivery end can be kept, the medicine delivery end does not make contact with the external environment, the end can be conveniently and firmly connected and rapidly disassembled and assembled, then disinfection treatment is convenient, meanwhile, the medicine delivery speed can be controlled, and medicine delivery is uniform.

The invention belongs to the technical field of biotechnology and pharmaceutical preparations, and particularly relates to a composition, nanoparticles, a medicine and a medicine system for treating HPV infection. The composition for resisting HPV infection comprises lactoglobulin coupled with a combined antibody and anti-cervicitis pathogen IgY (Immunoglobulin Y), based on the three-in-one antibody combination, the curative effect of immunotherapy can be remarkably improved, the actual curative effect of the combined preparation is greatly improved through the synergistic effect of the three antibodies, the treatment effect of HPV infection is effectively improved, and the combined preparation can be used for preparing drugs and drug systems for resisting HPV infection.

The invention discloses a preparation method of a gel preparation for improving cervical HPV infection and establishing a prevention barrier, relates to the technical field of preparation of gel preparations, and aims to solve the problems that most of existing treatment methods focus on treatment of infected patients, and the existing treatment methods have a poor treatment effect on prevention of HPV infection, especially establishment of an effective prevention barrier in uninfected people. The raw material crushing device comprises a crushing mechanism which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel to work is arranged on the cabinet door; and the reverse osmosis mechanism is mainly used for controlling the gel osmotic pressure. The invention has the advantages of activating local immune cells of the cervix uteri, promoting the secretion of cell factors, enhancing the immune clearance ability of the body to the HPV virus, providing long-acting prevention and protection for the cervix uteri, and reducing the HPV infection risk.

The invention provides a therapeutic target for high-risk human papilloma virus infection diseases and application of the therapeutic target. The important pathogenic factor EC-HPV16 / 18-Fs of the human papilloma virus infection disease is determined, and the pathogenic factor EC-HPV16 / 18-Fs can be used as a target to prepare a targeted regulation reagent for treating the human papilloma virus infection disease; or, a reagent for targeted regulation is screened by taking the target as a target. The invention also provides nucleic acid inhibitors for targeted modulation. The invention provides a new target for clinical treatment and detection of human papilloma virus infection diseases.

The invention provides a HPV mRNA lipid nanoparticle vaccine, comprising an open reading frame encoding a fusion protein of E2, E6 and E7 antigens of a high-risk HPV antigen. The invention also provides a method for treating and preventing HPV infection related diseases such as cervical cancer, cervical precancerous lesions, high-grade intraepithelial lesions of the cervix, high-grade squamous intraepithelial lesions (HSIL) or cervical intraepithelial neoplasia (CIN).

Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.

This invention discloses a composition and its preparation method for treating human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN), belonging to the field of traditional Chinese medicine technology. The formula consists of 6-15 parts of American cockroach, 5-11 parts of hawthorn, 5-11 parts of chicory, 3-9 parts of *Scutellaria baicalensis*, 8-20 parts of *Sophora flavescens*, and 6-15 parts of *Cnidium monnieri*, and also contains 0.01-1 parts by weight of toad venom. The dosage form is one or more of the following: external gel, rinse, foam, suppository, and film preparation. It has high safety and is suitable for HPV infection and CIN changes, solving the problem of poor efficacy in existing treatments.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

The application discloses a recombinant humanized collagen composition for resisting HPV infection and a preparation method thereof. The composition comprises the following components in percentage by mass: 30-45% of a recombinant humanized collagen fusion protein, 30-40% of probiotics and 20-35% of glycogen. The recombinant humanized collagen fusion protein comprises, from N-terminal to C-terminal, a recombinant humanized collagen fragment and a human fibronectin fragment connected in sequence. The recombinant humanized collagen fragment and the human fibronectin fragment are connected by a linker. The recombinant humanized collagen fusion protein in the composition can promote the adhesion and colonization of the probiotic composition to the vaginal epithelial cells, rapidly improve the microbial environment of the vagina and effectively enhance the resistance of the vagina to harmful bacteria and viruses.

The invention discloses a B cell conservative epitope peptide LF7 of human papilloma virus (HPV) L1 protein and application of the B cell conservative epitope peptide LF7 in HPV infection early-stage antibody detection. An agglutination test antibody detection system based on direct mediation of an LF7-antibody is constructed by displaying and expressing LF7 on the surface of an inert vector bacterium S9H, the detection system can specifically detect and monitor HPV infection early infectious antibodies and does not have cross reaction with other pathogen infection positive serum antibodies, and by taking the inert vector bacterium S9H which does not express LF7 epitope peptide as a contrast, the detection system can detect and monitor HPV infection early infectious antibodies and does not have cross reaction with other pathogen infection positive serum antibodies. The reaction with infectious antibodies is also avoided. In the detection of a positive serum sample at the early stage of HPV infection, the detection positive rate is 100%. The antibody detection system has the advantages of strong specificity and high sensitivity, can quickly and accurately detect the HPV infection early infectious antibody, and can quantitatively determine the titer of the antibody. The invention provides efficient and reliable technical support for early accurate diagnosis of HPV infection, and has important clinical application value.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to an external traditional Chinese medicine composition for resisting HPV infection as well as a preparation method, a component analysis method and application thereof. The external traditional Chinese medicine composition is prepared from the following raw materials: rhizoma atractylodis, cortex phellodendri, radix sophorae flavescentis, rhizoma coptidis, rhizoma polygoni cuspidati, herba taraxaci, humifuse euphorbia herb, herba selaginellae, semen juglandis and fructus cnidii, all the medicines are used together, both symptoms and root causes are taken into consideration, middle-jiao can be healthy to prevent endogenesis of damp evil, lower-jiao can be cleared to remove damp-heat and excess syndromes, and the external traditional Chinese medicine composition has the effects of detoxifying and resisting viruses and conforms to the pathogenesis characteristics of HPV infection. The external traditional Chinese medicine composition can directly act on a lesion part through a mucous membrane drug delivery system by being directly applied to an affected part, the treatment effect is remarkable, and gastrointestinal discomfort caused by oral medicine can be reduced.